Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With Cefazolin and Ceftriaxone

Shawnalyn W Sunagawa; Sarah Arduser; Molly M Miller; Elizabeth Lyden; Melissa LeMaster; Nicolas Cortes-Penfield; Richard J Hankins; Scott J Bergman; Bryan T Alexander

doi:10.1093/ofid/ofad606

Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With Cefazolin and Ceftriaxone

Open Forum Infect Dis. 2023 Dec 2;10(12):ofad606. doi: 10.1093/ofid/ofad606. eCollection 2023 Dec.

Authors

Affiliations

¹ Department of Pharmaceutical and Nutrition Care, Nebraska Medicine, Omaha, Nebraska, USA.
² College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
³ College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.
⁴ Divison of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Abstract

The optimal laboratory monitoring frequency for outpatient parenteral antimicrobial therapy-related adverse events (OPAT-AEs) during cefazolin and ceftriaxone therapy is not well defined. We identified 2.7 OPAT-AEs per 1000 sets of weekly laboratory tests in this population, suggesting that less intensive laboratory monitoring may be safe and reasonable.

Keywords: adverse events; cefazolin; ceftriaxone; laboratory techniques and procedures; outpatient parenternal antimicrobial therapy.